Key result
Higher serum PTX3 levels independently predicted incident chronic kidney disease after 5 years in both the PIVUS (OR 1.21; 95% CI 1.01-1.45) and ULSAM (OR 1.37; 95% CI 1.07-1.77) cohorts.
Why the study?
Whether pentraxin 3 levels predict worsening kidney function and incident chronic kidney disease in the elderly was less well studied.
Do higher levels of pentraxin 3 (PTX3) predict incident chronic kidney disease in elderly subjects?
Cohort (n=1,419)
Yes
Do higher levels of pentraxin 3 (PTX3) predict incident chronic kidney disease in elderly subjects?
Odds Ratio: 1.21 (95% CI 1.01–1.45)
p-value: p=< 0.05
Higher circulating PTX3 levels are associated with lower GFR and independently predict incident CKD in elderly individuals, suggesting its potential as a biomarker for early kidney disease.
OBJECTIVE: Higher levels of the novel inflammatory marker pentraxin 3 (PTX3) predict cardiovascular mortality in patients with chronic kidney disease (CKD). Yet, whether PTX3 predicts worsening of kidney function has been less well studied. We therefore investigated the associations between PTX3 levels, kidney disease measures and CKD incidence. METHODS: Cross-sectional associations between serum PTX3 levels, urinary albumin/creatinine ratio (ACR) and cystatin C-estimated glomerular filtration rate (GFR) were assessed in two independent community-based cohorts of elderly subjects: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS, n = 768, 51% women, mean age 75 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM, n = 651, mean age 77 years). The longitudinal association between PTX3 level at baseline and incident CKD (GFR <60 mL(-1) min(-1) 1.73 m(-2) was also analysed (number of events/number at risk: PIVUS 229/746, ULSAM 206/315). RESULTS: PTX3 levels were inversely associated with GFR [PIVUS: B-coefficient per 1 SD increase -0.16, 95% confidence interval (CI) -0.23 to -0.10, P < 0.001; ULSAM: B-coefficient per 1 SD increase -0.09, 95% CI -0.16 to -0.01, P < 0.05], but not ACR, after adjusting for age, gender, C-reactive protein and prevalent cardiovascular disease in cross-sectional analyses. In longitudinal analyses, PTX3 levels predicted incident CKD after 5 years in both cohorts [PIVUS: multivariable odds ratio (OR) 1.21, 95% CI 1.01-1.45, P < 0.05; ULSAM: multivariable OR 1.37, 95% CI 1.07-1.77, P < 0.05]. CONCLUSIONS: Higher PTX3 levels are associated with lower GFR and independently predict incident CKD in elderly men and women. Our data confirm and extend previous evidence suggesting that inflammatory processes are activated in the early stages of CKD and drive impairment of kidney function. Circulating PTX3 appears to be a promising biomarker of kidney disease.
No takes yet. Share an insight, caveat, or question.
Janerot-Sjöberg et al. (2015) conducted a cohort in Chronic kidney disease (n=1,419). Serum pentraxin 3 (PTX3) levels vs. Lower PTX3 levels was evaluated on Incident CKD (GFR <60 mL/min/1.73 m2) (OR 1.21, 95% CI 1.01-1.45, p=< 0.05). Higher serum PTX3 levels independently predicted incident chronic kidney disease after 5 years in both the PIVUS (OR 1.21; 95% CI 1.01-1.45) and ULSAM (OR 1.37; 95% CI 1.07-1.77) cohorts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: